Liquid-Phase Peptide Synthesis (LPPS)

Liquid-phase peptide synthesis assembles a chain in homogeneous solution instead of on a solid support. Each protected amino acid or fragment is coupled in a flask, and the growing intermediate is isolated and purified between steps by crystallisation, precipitation or extraction. Routes are frequently convergent: two or three protected fragments are built separately and condensed near the end, rather than adding one residue at a time from a fixed anchor point.

It is the older chemistry and it is not obsolete. The first chemical synthesis of oxytocin, reported by du Vigneaud in 1953, was solution-phase work that predates Merrifield's resin by a decade. Solution and hybrid solution-solid routes remain the industrial default for short sequences and for the fragment couplings used at multi-kilogram scale, where the reagent excesses and solvent volumes of stepwise resin chemistry become the dominant cost.

The tradeoff is purification effort against material efficiency. Isolating an intermediate at every stage removes failure sequences early, so the final crude can be cleaner than a resin-derived crude of the same length, but each isolation costs a unit operation and some yield. That arithmetic favours solution chemistry for short peptides at scale and solid phase for long or research-scale sequences, which is why most published manufacturing routes for long analogues are hybrids of the two.

The misreading is treating the synthesis route as a quality grade. Neither method has an inherent purity; both produce deletion and truncation impurities, and both are judged by the same release testing. A listing that advertises solution-phase synthesis is describing a process choice, not a specification, and it says nothing about net peptide content, counterion load or endotoxin in the vial that arrives.